Ideaya Enrolls First Patient in Phase 1 Trial of KAT6/7 Dual Inhibitor IDE574
First patient enrolled in Ideaya Biosciences’ Phase 1 trial of IDE574, a dual KAT6/7 inhibitor for solid tumors, promising new oral cancer therapy.
2 minutes to read
Ideaya Biosciences Inc
Ideaya Biosciences Soars on Breakthroughs in Uveal Melanoma Treatment
Ideaya Biosciences’ stock surged after the company announced two significant breakthroughs in the treatment of uveal melanoma, a rare and aggressive eye cancer, with its drug darovasertib showing promising results in both neoadjuvant and first-line …
3 minutes to read
IDEAYA Biosciences: Navigating Financial Volatility in the Oncology Biotech Race
IDEAYA Biosciences, a biotech company focused on developing innovative cancer treatments, navigates a complex financial landscape and intense competition in the oncology sector, with its ability to overcome challenges and achieve commercial success …
3 minutes to read
IDEAYA Biosciences Advances Cancer Treatment with IND Submission for IDE892 and Strategic Partnership with Servier
IDEAYA Biosciences has made significant progress in cancer treatment with the submission of its new cancer drug, IDE892, and a strategic partnership with Servier to develop a treatment for eye cancer, highlighting the company’s commitment to innovat…
3 minutes to read
Ideaya Biosciences Inc. Poised to Revolutionize Cancer Treatment with Innovative Oncology Solutions
Ideaya Biosciences Inc. is a biotechnology company focused on developing innovative oncology treatments, with a strong financial foundation and a promising future in the fight against cancer.
2 minutes to read
IDEAYA Biosciences Reports Strong Q1 Results, Advances Oncology Pipeline with FDA Breakthrough Designation
IDEAYA Biosciences reported strong Q1 financial results, with $1.05 billion in cash reserves, and made significant progress in its oncology drug development pipeline, including FDA approvals and clinical trial enrollments.
2 minutes to read